Is it Time to Dump I-Mab ADR (IMAB) Stock After it Is Up 32.36% in a Week?

The market has been neutral on I-Mab ADR (IMAB) stock recently. IMAB gets a Neutral score from InvestorsObserver Stock Sentiment Indicator.

I-Mab ADR has a Neutral sentiment reading. Find out what this means for you and get the rest of the rankings on IMAB!

See Full IMAB Report

What is Stock Sentiment?

When making investment decisions, sentiment gives a good overview of what stocks investors currently favor. Sentiment incorporates short-term technical analysis into its score and does not encompass any fundamental analysis such as profitability of the company. This means that earnings updates and other news can greatly impact overall sentiment. Sentiment is how investors, or the market, feels about a stock. There are lots of ways to measure sentiment. At the core, sentiment is pretty easy to understand. If a stock is going up, investors must be bullish, while if it is going down, sentiment is bearish. InvestorsObserver’s Sentiment Indicator looks at price trends over the past week and also considers changes in volume. Increasing volume can mean a trend is getting stronger, while decreasing volume can mean a trend is nearing a conclusion. For stocks that have options, our system also considers the balance between calls, which are often bets that the price will go up, and puts, which are frequently bets that the price will fall.

What's Happening With IMAB Stock Today?

I-Mab ADR (IMAB) stock is trading at $11.78 as of 2:16 PM on Tuesday, Jun 21, a gain of $0.75, or 6.8% from the previous closing price of $11.03. The stock has traded between $11.22 and $12.01 so far today. Volume today is light. So far 436,752 shares have traded compared to average volume of 1,258,749 shares.

More About I-Mab ADR

I-Mab Biopharma is a clinical-stage biotech company in China that listed on Nasdaq in January 2020. Its first commercial drug will be felzartamab for the China market, a CD38 inhibitor for multiple myeloma, which we estimate will be launched in late 2023 or ealry 2024. Core assets include lemzoparlimab, a potential best-in-class CD47 inhibitor; uliledlimab, a potential best-in-class CD73 inhibitor; and eftansomatropin, a long-acting growth hormone that has a large market in China among pediatric patients with short stature. Click Here to get the full Stock Report for I-Mab ADR stock.